Unifor Reaches Tentative GM Deal for 4,600 Ontario Workers 
Unitree Robotics Shares Soar Over 600% in Shanghai Market Debut 
Anthropic IPO Could Challenge SpaceX’s Record $86 Billion Offering 
Apple Cuts Over 200 Siri, Vision Pro Jobs in AI Shift 
Moody’s Affirms NVIDIA Aa1 Rating as AI Data Center Guarantees Reach $105 Billion 
Alibaba Shares Fall as AI Spending Hits Profit 
Coty Revenue Beats Estimates as Beauty Demand Holds Firm 
Nordson Stock Rises as Q3 Earnings Beat Estimates, Outlook Raised 
OpenAI Revenue Rises 18% in Q2 as Losses Widen and Anthropic Surges Ahead 
REPAY Stock Rises After Visa Platform Connect Collaboration 
SpaceX Hires Natural Gas Trader to Meet Growing Energy Needs 
TikTok, DOJ Reach $400 Million Children’s Privacy Settlement 
Amazon to Expand Drone Delivery to 500 U.S. Locations 
Toyota, Honda Shares Rise on Possible U.S.-Canada Auto Tariff Cut 
Baidu Shares Sink to One-Year Low as Ad Weakness Overshadows AI Growth 
OpenAI Tightens AI Safety Monitoring After Security Incidents 
Moody’s Upgrades Vodafone Hybrid Debt Ratings to Baa3 
Add as a preferred source on Google
LONDON and CARLSBAD, Calif., May 08, 2018 -- GW Pharmaceuticals plc (NASDAQ:GWPH) (GW, the Company or the Group), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced that GW management will present at the Bank of America Merrill Lynch 2018 Health Care Conference on Tuesday, May 15, 2018 at 1:00 p.m. PT in Las Vegas, Nevada.
A live audio webcast of the presentation will be available through GW’s corporate website in the investor relations section from the investor’s calendar of events page at www.gwpharm.com. A replay will be available soon after the live presentation.
About GW Pharmaceuticals plc and Greenwich Biosciences
Founded in 1998, GW is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. GW, along with its U.S. subsidiary Greenwich Biosciences, is advancing an orphan drug program in the field of childhood-onset epilepsy with a focus on Epidiolex (cannabidiol), for which GW has submitted regulatory applications in the U.S. and Europe for the adjunctive treatment of Lennox-Gastaut syndrome and Dravet syndrome. The Company continues to evaluate Epidiolex in additional rare epilepsy conditions and currently has ongoing clinical trials in Tuberous Sclerosis Complex and Infantile Spasms. GW commercialized the world’s first plant-derived cannabinoid prescription drug, Sativex® (nabiximols), which is approved for the treatment of spasticity due to multiple sclerosis in numerous countries outside the United States and for which the company is now planning a US Phase 3 trial. The Company has a deep pipeline of additional cannabinoid product candidates which includes compounds in Phase 1 and 2 trials for epilepsy, glioblastoma, and schizophrenia. For further information, please visit www.gwpharm.com.
Enquiries:
| GW Pharmaceuticals plc | |
| Stephen Schultz, VP Investor Relations (U.S.) | 917 280 2424 / 401 500 6570 |
